MorphoSys AG buy piccolo90
Summary
This prediction ended on 24.09.12 with a price of €24.00. The BUY prediction by piccolo90 for MorphoSys AG saw massive gains of 40.33%. piccolo90 has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | 0.148% | 0.148% | 256.110% | -10.902% |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% | 16.867% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% | 45.898% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% | 2.760% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% | 42.955% |
Comments by piccolo90 for this prediction
In the thread Morphosys AG diskutieren
Neue Chancen zum Anstieg
Morphosys hat durch eine Enwicklungspartnerschaft mit Roche zur Behandung von Alzheimer -Patienten einen neuen Meilenstein gesetzt.